J Bone Metab.  2014 Aug;21(3):223-226. 10.11005/jbm.2014.21.3.223.

Intravenous Zoledronate for a Patient with Paget's Disease

• Kim KC

• KMID: 2286293
• DOI: http://doi.org/10.11005/jbm.2014.21.3.223

Abstract

Paget's disease (PD) of bone is characterized by increase of bone resorption by atypical osteoclasts, followed by rapid new bone formation resulting in a disorganized mosaic bone. Although the pathophysiology is not fully understood, bisphosphonate, which is a potent anti-resorptive agent for treatment of osteoporosis, have been the most effective agents available for the treatment of PD. We report a case of PD of bone in a 49-year-old woman patient, who was treated with intravenous zoledronate.

Keyword

Bone density conservation agents; Diphosphonates; Osteitis deformans

MeSH Terms

Bone Density Conservation Agents
Bone Resorption
Diphosphonates
Female
Humans
Middle Aged
Osteitis Deformans
Osteoclasts
Osteogenesis
Osteoporosis
Bone Density Conservation Agents
Diphosphonates

Reference

1. Lyles KW, Siris ES, Singer FR, et al. A clinical approach to diagnosis and management of Paget's disease of bone. J Bone Miner Res. 2001; 16:1379–1387.

2. Cundy T, Reid IR. Paget's disease of bone. Clin Biochem. 2012; 45:43–48.

3. Ralston SH, Langston AL, Reid IR. Pathogenesis and management of Paget's disease of bone. Lancet. 2008; 372:155–163.

4. Galson DL, Roodman GD. Pathobiology of Paget's Disease of Bone. J Bone Metab. 2014; 21:85–98.

5. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356:1809–1822.

6. Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007; 357:1799–1809.

7. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002; 346:653–661.

8. Tucci JR. Therapy with zoledronic acid, 5 mg, for a patient with Paget disease of bone. Endocr Pract. 2008; 14:607–610.

9. Boonen S, Vanderschueren D, Venken K, et al. Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance. J Intern Med. 2008; 264:315–332.

10. Kamatari M, Koto S, Ozawa N, et al. Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate. J Bone Miner Metab. 2007; 25:302–309.

11. Kertes J, Dushenat M, Vesterman JL, et al. Factors contributing to compliance with osteoporosis medication. Isr Med Assoc J. 2008; 10:207–213.

12. Reid IR, Miller P, Lyles K, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med. 2005; 353:898–908.

13. Hosking D, Lyles K, Brown JP, et al. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res. 2007; 22:142–148.

14. Lee YK, Nho JH, Ha YC, et al. Persistence with intravenous zoledronate in elderly patients with osteoporosis. Osteoporos Int. 2012; 23:2329–2333.

15. Lee YK, Kim KC, Choi HY, et al. Intravenous zolendronic acid for the patients treated operatively after hip fracture: a short-term safety prospective cohort study. J Korean Hip Soc. 2008; 20:305–310.